Unpacking Digital Medicine

Emily BurkeCardiovascular Disease, Diabetes, FDA, Medical Device

CAN APPS PROGRAM BETTER HEALTH? Digital medicine is defined by the field’s pioneer Dr. Eric Tool of the Scripps Translational Science Institute (La Jolla, CA) as “the ability to digitize human beings, by a variety of means (sequencing, sensors, imaging, etc.), fully exploiting our digital infrastructure of ever-increasing bandwidth, connectivity, social networking, the Internet of all things, and health information systems.” This new field is changing the way … Read More

Unwiring The Biology Of Fibrosis

Emily BurkeAntisense, Biologics, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs, Term of the Week, The WEEKLY

Fibrotic Disease Innovations Fibrotic diseases — organ and tissue disorders that occur as a result of the buildup of excessive scar tissue — are sounding the alarm in the biotech sector. A silent epidemic creeping up on the Western world involves non-alcoholic steatohepatitis (NASH), or liver fibrosis associated with obesity and type 2 diabetes. Left untreated, NASH can lead to liver failure. Currently, … Read More

The Molecular Cause Of Obesity

Emily BurkeClinical Trials, Diabetes, Drug Development, Drug Targets, Mechanism of Action, Term of the Week

Targeting Fat Obesity is considered one of the most pressing public health issues of the day. According to the Center for Disease Control, 37% of adults and 17% of children in the U.S. are obese. The latest drug interventions work by attempting to suppress food intake, which has proven beneficial for some. However, there is still a large unmet need … Read More

Disrupting The Cycle

Emily BurkeClinical Trials, Deoxyribonucleic Acid (DNA), Diabetes, Drug Development, Drug Targets, Mechanism of Action, Small Molecule Drugs, The WEEKLY

Circadian Rhythms Govern More Than 24 Hours Of Your Day Overnight shift workers, students pulling an all-nighter to cram for a final exam, and business people rushing between time zones all share one thing in common: significant disruption to their circadian rhythm. This roughly 24-hour activity cycle responds primarily to light and darkness and is found in most living organisms—people, … Read More

Stomach Stapling Paves A Pathway

Emily BurkeBiologics, Clinical Trials, Diabetes, Drug Development, Drug Targets, Mechanism of Action, The WEEKLY

Identifying Gut Proteins To Tackle Metabolic Disorders Historians of science love to tell about “eureka moments”—simple observations leading to major insight. Greek mathematician Archimedes allegedly exclaimed the original “Eureka!”—meaning “I have found it!”—upon witnessing the volume of water displaced by his body in the bathtub equaled the volume of the body part he had submerged. Medicine’s most famous eureka moment is probably the … Read More

Longevity In Biotech

Emily BurkeBiologics, Business of Biotech, Cancer, Clinical Trials, Drug Development, Drug Targets, Genomics, The WEEKLY

Longevity has fascinated mankind for centuries, from ancient myths about fountains of youth to current speculation around caloric restriction. With our increased scientific understanding of aging, clinical validation and commercialization of treatments are near. The goal is to extend lifespan as well as health span, and we may be looking at a future where the norm is to remain mentally and physically active at age 90, or even … Read More

Inhaling Insulin Is A Breath Of Fresh Air

Emily BurkeThe WEEKLY

INSULIN INHALED Injections are a part of life for most diabetics. Type 1 patients inject insulin into themselves multiple times per day, and as many as 40% of type 2 diabetics require at least one daily injection. Thanks to the FDA’s approval of MannKind Corporation’s inhalable insulin therapy called Afrezza, needles just might be a thing of the past for … Read More

Blunt Approach: Fecal Transplants

Emily BurkeThe WEEKLY

FECAL TRANSPLANTS: A BLUNT APPROACH The premise behind microbiome-based therapeutics is straightforward: identify differences in the microbiome of people suffering from a particular disease, and then try to make the sick person’s microbiome more like the healthy person’s. Rankings from the most radical (or just plain stomach-turning) to the most standard, here is a snapshot of microbiome-based therapeutics: Fecal transplants … Read More

No Free Lunch For Obesity Drugs

Emily BurkeThe WEEKLY

NO FREE LUNCH FOR OBESITY A major lead in curing obesity came on the scene in the 1990s when researchers noticed that obese mice lacked a critical hormone dubbed leptin. Suddenly, the tantalizing prospect of tackling obesity with leptin treatments sent both drug developers and casual dieters astir. As the saying goes, there’s no free lunch, and excitement waned in recent … Read More